The phosphotyrosine interaction (PI) domains (also known as the PTB, or phosphotyrosine binding, domains) of Shc and IRS-1 are recently described domains that bind peptides phosphorylated on tyrosine residues. The PI/PTB domains differ from Src homology 2 (SH2) domains in that their binding specificity is determined by residues that lie amino terminal and not carboxy terminal to the phosphotyrosine. Recently, it has been appreciated that other cytoplasmic proteins also contain PI domains. We now show that the PI domain of X11 and one of the PI domains of FE65, two neuronal proteins, bind to the cytoplasmic domain of the amyloid precursor protein (␤APP). ␤APP is an integral transmembrane glycoprotein whose cellular function is unknown. One of the processing pathways of ␤APP leads to the secretion of A␤, the major constituent of the amyloid deposited in the brain parenchyma and vessel walls of Alzheimer's disease patients. We have found that the X11 PI domain binds a YENPTY motif in the intracellular domain of ␤APP that is strikingly similar to the NPXY motifs that bind the Shc and IRS-1 PI/PTB domains. Protein-protein interactions are important in signaling by many cell surface receptors. For example, activated growth factor receptors bind several signaling proteins in a phosphotyrosine-dependent fashion. Many of these signaling proteins contain Src homology 2 (SH2) domains that mediate the interaction with growth factor receptors by binding to specific phosphopeptide sequences present on the receptors (40, 45). Our laboratory has been cloning receptor-binding proteins by screening bacterial expression libraries with the tyrosine-phosphorylated epidermal growth factor (EGF) receptor. In general, this approach has led to the cloning of genes that encode SH2-domain proteins (33, 36, 39, 47) . However, recently, our group and others have identified a new phosphotyrosine interaction/phosphotyrosine binding (PI/PTB) domain in the protein Shc (3, 23, 28). Shc has an important role in tyrosine kinase signal transduction. Shc becomes tyrosine phosphorylated upon activation of many growth factors, cytokines, and G-protein-coupled receptors (12, 14, 32, 41, 43, 55) . The tyrosine phosphorylation of Shc allows it to bind Grb2, which begins a cascade leading to the activation of Ras and mitogenactivated protein kinase pathways (43). The PI/PTB domain found in the amino terminus of Shc appears to be crucial for the interaction of Shc with EGF receptor, nerve growth factor receptor, and insulin receptor (1, 3, 13, 16, 52, 54) .
Protein-protein interactions are important in signaling by many cell surface receptors. For example, activated growth factor receptors bind several signaling proteins in a phosphotyrosine-dependent fashion. Many of these signaling proteins contain Src homology 2 (SH2) domains that mediate the interaction with growth factor receptors by binding to specific phosphopeptide sequences present on the receptors (40, 45) . Our laboratory has been cloning receptor-binding proteins by screening bacterial expression libraries with the tyrosine-phosphorylated epidermal growth factor (EGF) receptor. In general, this approach has led to the cloning of genes that encode SH2-domain proteins (33, 36, 39, 47) . However, recently, our group and others have identified a new phosphotyrosine interaction/phosphotyrosine binding (PI/PTB) domain in the protein Shc (3, 23, 28) . Shc has an important role in tyrosine kinase signal transduction. Shc becomes tyrosine phosphorylated upon activation of many growth factors, cytokines, and G-protein-coupled receptors (12, 14, 32, 41, 43, 55) . The tyrosine phosphorylation of Shc allows it to bind Grb2, which begins a cascade leading to the activation of Ras and mitogenactivated protein kinase pathways (43) . The PI/PTB domain found in the amino terminus of Shc appears to be crucial for the interaction of Shc with EGF receptor, nerve growth factor receptor, and insulin receptor (1, 3, 13, 16, 52, 54) .
Although both PI/PTB domains and SH2 domains bind to phosphotyrosine-containing peptides, their binding specificities and tertiary structures are completely different (48, 56, 59) . While SH2 domain binding specificity is determined by residues that lie carboxy terminal to the phosphotyrosine, the Shc PI/PTB domain specificity is determined by residues amino terminal to the phosphotyrosine. The binding specificity for the Shc PI/PTB is the sequence ⌿XNPXpY (where ⌿ is a hydrophobic residue, N is asparagine, P is proline, X is any amino acid, and pY is phosphotyrosine) (1, 16, 25, 53, 57) . These sequences are found on several growth factor receptors, including the nerve growth factor receptor and EGF receptor (1, 16, 54) . Studies have indicated that the hydrophobic residue in the Ϫ5 position (i.e., 5 residues amino terminal to the phosphotyrosine), the asparagine in the Ϫ3 position, and the phosphotyrosine are crucial for the interaction with the PI/PTB domain of Shc. Our group has examined the residues in the Shc PI/PTB domain critical for interaction with phosphopeptide, using random mutagenesis. A phenylalanine at residue 198 of p52 Shc that is essential for the interaction with phosphopeptides was identified (58) . A recent structural analysis of the Shc PI/PTB domain confirms the importance of this phenylalanine in directly contacting the ⌿XNPXpY peptide by interacting with the hydrophobic amino acid at position Ϫ5 and the asparagine at Ϫ3 relative to the phosphotyrosine (59) .
Mutations of this phenylalanine (F-198) abolish the ability of Shc to interact with EGF receptor or to become tyrosine phosphorylated by insulin receptor (26, 58) . Other residues critical for the interaction of the Shc PI/PTB domain with phosphotyrosine-containing peptides have been identified by other groups (53, 59) . We have identified several other proteins that contain PI domains (4) . All of the PI domains identified have two conserved residues found in the Shc PI/PTB domain, a glycine found at residue 58 and a serine at residue 151 of p52 Shc. Additionally, all PI domains except for the ones found in the FE65 proteins have phenylalanine at a position analogous to F-198 of Shc (58) . FE65 proteins have two PI domains, and both contain cysteine rather than phenylalanine at this position. FE65 is a neuron-specific protein that originally was considered to be a transcriptional activator (19) . However, an additional function was suggested when it was found that the PI domains of FE65 can interact with the cytoplasmic domain of the amyloid precursor protein ␤APP (20) . ␤APP resembles an integral, glycosylated cell surface receptor with a single membrane-spanning region and a short C-terminal cytoplasmic domain (27) . Proteolytic processing of ␤APP results in the generation of A␤, which is composed of 28 residues of the putative extracellular domain and 11 to 15 residues of the transmembrane domain of ␤APP. A␤ is the major constituent of the amyloid deposited extracellularly in the brain parenchyma and vessel walls of Alzheimer's disease patients (21, 37) . One of the proteolytic processing pathways of ␤APP was suggested to occur following internalization of the protein (24, 29) . The YENPTY motif found in the cytoplasmic domain of ␤APP may have a role in the internalization of the protein, and deletion of this sequence affects the production of A␤ (15, 29, 31) . The YENPTY sequence of ␤APP is surprisingly similar to the sequence that binds the Shc PI/PTB domain. Consequently, in this study, we undertook to further analyze the interaction of PI domains with ␤APP. We have found that not only does the PI domain of FE65 bind to ␤APP but also the PI domain of X11, another neuronal protein, interacts with ␤APP. The binding of both X11 and FE65 does not depend on phosphorylation of ␤APP and involves the YENPTY residues of ␤APP.
MATERIALS AND METHODS
Antibodies. Anti-Myc monoclonal antibody (MAb) 9E10 (Oncogene Science) directed against a peptide with the sequence MEQKLISEEDLN was used for immunoprecipitation and immunoblotting. To analyze ␤APP, two antibodies were used for immunoprecipitation and immunoblotting: 6E10, a MAb (Senetec), and 369, a polyclonal antiserum (7) . To analyze EGF receptor, MAb 108 was used for immunoprecipitation while antipeptide antibody anti-C was used for immunoblotting as previously described (34) . Polyclonal anti-glutathione S-transferase (anti-GST) antibody was prepared by injecting rabbits with the purified protein.
Cell culture. Human embryonic kidney 293 and HER14 cells (NIH 3T3 cells overexpressing EGF receptor) were grown in Dulbecco modified Eagle medium (DMEM) containing 100 U of penicillin ml Ϫ1 and 100 g of streptomycin sulfate ml Ϫ1 supplemented with 10% fetal calf serum and calf serum, respectively. PC12 cells were maintained in DMEM plus antiobiotics, supplemented with 10% fetal calf serum and 5% horse serum. For EGF stimulation, HER14 cells were starved overnight in DMEM with 0.5% calf serum and stimulated for 3 min at 37ЊC with 100 ng of recombinant human EGF (Intergen) ml
Ϫ1
. DNA constructs and mutagenesis. An RK5-myc vector was generated by cloning a 92-bp insert into a eucaryote-expressing RK5 vector, creating an ME QKLISEEDLLEGSPGILD coding sequence. The myc epitope is preceded by a Kozak sequence and followed by sites allowing cloning of cDNAs. For the RK5-myc-X11 construct, human X11 cDNA was digested with AccI enzyme, cutting the cDNA 26 bp downstream of the putative start codon (18) and removing 9 amino-terminal amino acids of X11 coding sequence. The blunted AccI site was then cloned in frame into an RK5-myc SmaI site. For the RK5-myc-X11⌬PDZ construct, we utilized an EcoRI site present just after the X11 PI domain to remove the PDZ coding sequence (nucleotide 1453 to the stop codon). Rat FE65 cDNA was cloned by reverse transcription-PCR from PC12 cell RNA and directly C-terminally myc tagged by use of an appropriate reverse primer before being cloned into RK5 vector. For GST fusion proteins, cDNAs encoding isolated PI domains were cloned into PGEX-2T (Pharmacia) or PGSTag (42) after cloning sites were created by PCR. GST-␤APP 597-638 contains the 42 amino acids of A␤, and GST-␤APP 649-695 contains the whole ␤APP cytoplasmic domain (see Fig. 5 ). GST-Shc PI and GST-Grb2 have been described elsewhere (2, 3) . For mutagenesis, we used a Transformer site-directed mutagenesis kit (Clontech) or a USE mutagenesis kit (Pharmacia). All constructs were sequenced by using Sequenase version 2.0 (U.S. Biochemical Corp.).
Immunoprecipitation and immunoblotting.
Cells were washed twice with cold phosphate-buffered saline (PBS) and lysed in lysis buffer [50 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid; pH 7.5), 10% glycerol, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM ethylene glycol-bis(␤-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA)] supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin ml
Ϫ1
, and 10 g of leupeptin ml Ϫ1 . For HER14 lysis, 100 mM NaF, 200 M sodium orthovanadate, and 10 mM tetrasodium PP i were added to the lysis buffer. After centrifugation at 16,000 ϫ g for 20 min, the lysate protein content was normalized by using a Bio-Rad protein assay kit. For immunoprecipitation, lysates were incubated with antibodies for 2 h at 4ЊC with anti-␤APP (MAb 6E10) or anti-EGF receptor (MAb 108) antibodies and overnight with anti-myc antibody. Protein A-agarose was added, and immune complexes bound to beads were recovered after 1 h, washed three times with lysis buffer, boiled in 1ϫ sample buffer, and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Transfer and immunoblotting on nitrocellulose using a horseradish peroxidase-protein A or horseradish peroxidase-anti-mouse antibody chemiluminescence method were performed as described elsewhere (35) .
Metabolic labeling. After 1 h in methionine-free DMEM containing 3% fetal bovine serum, cells were metabolically labeled at 37ЊC for 4 h with [
35 S]methionine (80 Ci ⅐ ml Ϫ1 ) in the same medium. The cells were then rinsed with ice-cold PBS and lysed in lysis buffer with protease inhibitors. After precipitation with antibody or GST, proteins were resolved on SDS-10% polyacrylamide gels treated with Amplify (Amersham) prior to being dried and exposed to X-ray film (Kodak XAR).
GST binding assay. GST fusion proteins were expressed by standard techniques (2). Proteins were either used for binding assays on glutathione agarose beads or eluted with 15 mM glutathione buffer. Lysates were incubated with GST fusion proteins bound to glutathione agarose beads for 2 h at 4ЊC. The beads were then washed three times with lysis buffer, boiled in 1ϫ sample buffer, and separated by SDS-PAGE. For peptide competition, increased amounts of peptide were incubated with the beads for 1 h at 4ЊC before addition of cell lysates. After 2 h at 4ЊC, bound proteins were washed three times with lysis buffer and separated by SDS-PAGE. In all experiments, the presence of comparable amounts of GST was verified by Western blotting (immunoblotting) with anti-GST or Ponceau Red staining of the membrane.
Transfection. 293 cells were seeded a day before transfection at approximately 10 6 /10-cm-diameter plate and then transfected with 10 to 20 g of DNA by using calcium phosphate (9) . The cells were lysed 48 h after transfection with lysis buffer.
In vitro dephosphorylation assay. MAbs 6E10 and 108 were used to immunoprecipitate ␤APP and EGF receptor from cell lysates, respectively. After being washed with potato acid phosphatase (PAP) buffer (20 mM Tris [pH 7.4], 5% glycerol, 0.05% Triton X-100, 2.5 mM MgCl 2 ), immunoprecipitates were treated with 4 g of PAP for 30 min at 37ЊC in 50 l of PAP buffer supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin ml Ϫ1 , and 10 g of leupeptin ml
Ϫ1 . The phosphatase reaction was stopped by washing the beads three times with cold lysis buffer. Lysis buffer (500 l) containing 0.5 to 1 g of soluble GST was then added, and the mixture was incubated for 2 h at 4ЊC. The beads were washed three times with lysis buffer and resuspended in 1ϫ sample buffer, and bound proteins were subjected to Western blotting.
RESULTS
FE65 is a neuronally expressed protein with two PI domains as well as a WW domain (Fig. 1A) (19, 51) . Recent data suggested that FE65 PI domains could interact with the cytoplasmic domain of amyloid precursor protein (␤APP), although it was not clear if the amino-or carboxy-terminal PI domain was responsible for the binding (20) . Individual PI domains of FE65 were prepared as GST fusion proteins and studied for their ability to bind to ␤APP. We also prepared several fusion proteins containing other PI domains and evaluated their ability to bind to ␤APP. Figure 1B shows the results of such a binding experiment using either GST or GST fusion proteins with Grb2, the Shc PI domain, the X11 PI domain, the amino-terminal FE65 PI domain [FE65 PI (N)], or the carboxy-terminal FE65 PI domain [FE65 PI (C)]. These fusion proteins were immobilized on glutathione agarose beads and incubated with lysates from cells that overexpressed ␤APP. We found that the X11 PI domain as well as FE65 PI (C) and (NϩC) (data not shown) could bind to ␤APP, whereas the Shc PI domain, Grb2, or FE65 PI (N) could not. We also found no binding of the PI domains of p96 or Numb to ␤APP (results not shown). In Fig. 1C , we show results for a control in which the same GST fusion proteins were incubated with lysates from HER14 cells, treated or not treated with EGF. We demonstrate that both Grb2 and the Shc PI domain can bind to EGF receptor from activated cells but that none of the other PI domains tested bind to EGF receptor from either unstimulated or stimulated cells. X11 has only one PI domain but has two PDZ domains (Fig. 1A) . Like the WW domain of FE65, PDZ domains have been implicated in protein-protein interactions (5, 6, 10, 17, 30, 44, (49) (50) (51) .
In the converse experiment, we examined the ability of bacterially expressed ␤APP to bind to full-length FE65 or X11 expressed in 293 cells. Both FE65 and X11 were constructed with an in-frame myc epitope to allow detection with an antimyc antibody. In addition, a myc-tagged X11 protein that was missing both PDZ domains was generated (X11⌬PDZ). Lysates with and without FE65-myc or X11-myc were added to beads coupled to GST alone, GST-Grb2, GST-␤APP 597-638 (representing the 42 amino acids of A␤), or GST-␤APP (representing the cytoplasmic domain of ␤APP). We found that GST-␤APP 649-695 , when expressed as a GST fusion protein in bacteria, could bind to full-length FE65, X11, or X11⌬PDZ (Fig. 2) . However, GST, GST-Grb2, or GST-␤APP 597-638 was not able to bind either X11 or FE65. We next analyzed whether full-length FE65 and X11 can interact with ␤APP in living cells (Fig. 3) . To perform these studies, we transfected 293 cells with plasmids encoding full-length FE65-myc or X11-myc and full-length ␤APP. As can be seen in Fig.   FIG. 1 . Structure of FE65 and X11 proteins and specificity of binding of PI domains to ␤APP. (A) Structure of full-length FE65 and X11 proteins. FE65 contains an N-terminal WW and two PI domains [(N) and (C)]. X11 contains a central PI domain followed at its carboxy-terminal end by two PDZ domains. The expressed proteins were epitope myc tagged in the carboxy-terminal position for FE65 (FE65-myc) and in the amino-terminal position for X11 (myc-X11). The myc-X11⌬PDZ protein is a truncated myc-X11 protein missing both PDZ domains. (B) ␤APP binds to X11 PI and FE65 PI (C) domains. Lysates of 293 cells transiently transfected with RK5 (Ϫ lanes) or RK5-␤APP 695 (ϩ lanes) were incubated with 5 g of recombinant GST proteins bound to glutathione-agarose beads. After a washing, the precipitated proteins were separated by SDS-10% PAGE and transferred to nitrocellulose. One-fifth of the lysates used for precipitation was directly run on the gel as a control (Lysate lanes). The membrane was probed with polyclonal 369 anti-␤APP antibody, and detection was performed by chemiluminescence. After being stripped, the membrane was probed with anti-GST antibody to confirm comparable amounts of GST in each assay (data not shown). An arrow indicates the position of ␤APP 695 protein. Positions of size markers are indicated (in kilodaltons) on the left. (C) Control binding of GST-Grb2 and GST-Shc PI domains to stimulated EGF receptor (EGF-R). EGF-stimulated HER14 lysates were incubated in the same conditions as for panel A. After Western blotting, the membrane was probed with anti-EGF receptor antibody. The position of the EGF receptor is indicated on the right. Note the shift of molecular mass of phosphorylated EGF receptor compared with that of unstimulated receptor in total lysate. VOL. 16, 1996 BINDING OF X11 AND FE65 TO ␤APP3A, immunoprecipitation of the myc-tagged FE65 with antimyc antibodies coimmunoprecipitated transfected ␤APP. For  Fig. 3B , we performed the same experiment using full-length X11 as well as X11⌬PDZ. We found that both forms of X11 could interact with ␤APP. In contrast, a myc-tagged Shc protein did not bind ␤APP (result not shown). Thus, X11 and FE65 can interact with ␤APP whether ␤APP is expressed in bacteria or in mammalian cells. As previously discussed, the PI domains of FE65 and X11 were first identified after a database search for sequences similar to the PI/PTB domain of Shc (4). These domains were initially called the PI domain, for phosphotyrosine interaction domain, or the PTB domain, for phosphotyrosine binding domain. However, the fact that the cytoplasmic domain of ␤APP when expressed in bacteria could bind to FE65 and X11 strongly suggested that tyrosine phosphorylation of ␤APP was not essential for binding. To further examine this question, the immunoprecipitated ␤APP from transfected 293 cells was treated with PAP to determine if dephosphorylation would affect the ability of ␤APP to bind to the PI domains of FE65 or X11. Treatment of ␤APP with PAP had no effect on the ability of ␤APP to bind the FE65 carboxy-terminal PI domain or X11 PI domain (Fig. 4A) . As a control, we examined the binding of EGF receptor to Grb2 to ensure that our PAP treatment was effective. In contrast to what was seen with ␤APP, PAP treatment of EGF receptor completely abolished the ability of EGF receptor to bind Grb2 (Fig. 4B) . These data indicate that ␤APP phosphorylation is not required for the interaction with the FE65 or X11 PI domain.
We next analyzed the binding sites on ␤APP for the X11 and FE65 PI domains, using site-directed mutagenesis of the cytoplasmic domain of ␤APP. Four of the mutations we engineered were point mutations, three of them centered on the YENPTY motif and one altering the tyrosine within the YTSI motif (Fig. 5A) . The other mutation placed a stop codon 18 amino acids from the carboxy terminus of ␤APP. These different mutations were placed in full-length ␤APP 695 , and the mutant proteins were expressed in 293 cells. The ability of the mutant forms of ␤APP to bind X11 or FE65 was then measured by incubating cell lysates with X11 or FE65 PI domain proteins immobilized on glutathione-agarose beads. As can be seen in Fig. 5B , deletion of the last 18 amino acids in the cytoplasmic domain of ␤APP (CD18) completely abolished the ability of FE65 and X11 PI domains to bind ␤APP. Similarly, the mutation of the tyrosine at residue 682 of ␤APP to glycine (Y682G) also severely inhibited the binding of both X11 and VOL. 16, 1996 BINDING OF X11 AND FE65 TO ␤APP 6233 FE65 PI domains. This tyrosine is the amino-terminal tyrosine of the sequence YENPTY. Mutation of asparagine of the YENPTY motif (N684A) had a differential effect on the binding of X11 and FE65 to ␤APP. While this mutation completely abolished the binding of X11, it had no effect on the binding of FE65. Mutation of the carboxy-terminal tyrosine in the YENPTY motif to alanine (Y687A) had almost no effect on the binding of X11 or FE65. Mutation of the tyrosine in the YTSI motif to alanine (Y653A) also had no effect on the binding of X11 or FE65. We next examined the ability of a peptide encompassing the YENPTY motif to compete with FE65 PI (C) and X11 PI domains for binding to ␤APP (Fig.   5C ). This peptide was able to compete with X11 with submicromolar affinity but had no effect on FE65 binding. A phosphopeptide with the carboxy-terminal tyrosine of the YENPTY motif phosphorylated blocked the binding of the X11 PI domain to ␤APP with the same affinity as a nonphosphorylated peptide (data not shown). Taken together, these results indicate that the FE65 and X11 PI domains have different binding specificities and that phosphotyrosine does not seem to be involved in the interaction of these PI domains with ␤APP. The ability of mutations within the PI domains to impact on the binding of FE65 and X11 to ␤APP was examined next. As discussed above, work from our laboratory has shown that the FIG. 4 . FE65 and X11 binding to ␤APP is independent of phosphorylation. (A) ␤APP 695 from transfected 293 cell lysates was precipitated by anti-␤APP MAb (6E10). After being washed, the beads were incubated in 50 l of PAP buffer with PAP (4 g) (ϩ PAP) or without PAP (Ϫ PAP) at 37ЊC for 30 min. The beads were then washed and incubated with soluble GST, GST-FE65 PI (C), or GST-X11 PI proteins. After 2 h, bound proteins were subjected to Western blot analysis. The results of 6E10 anti-␤APP and anti-GST blotting of the same membrane are shown (top and bottom panels, respectively). As a control, 1/10 of the amount of purified proteins used for binding was run on the gel and revealed with anti-GST antibody (right panel). (B) The same experiment was performed with EGF-stimulated HER14 lysates. Immunoprecipitated activated EGF receptors (EGFR) were incubated with or without PAP and then bound to GST or GST-Grb2. The results of the anti-EGF receptor and anti-GST blotting of the same membrane are shown (top and bottom panels, respectively). Pure GST proteins were run in parallel on the same gel and revealed with anti-GST antibody (right panels). Positions of size markers are indicated (in kilodaltons) on the left.
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phenylalanine found within the last alpha helix of the PI domain is very important for the binding of the Shc PI domain to phosphopeptide. The mutation of this phenylalanine to valine eliminates the binding of the Shc PI domain to EGF receptor and insulin receptor (26, 58) . Mutation of this phenylalanine (residue 479) to valine also eliminates the binding of the X11 PI domain to ␤APP (Fig. 6A) . Similarly, mutation of the cysteine at this position in FE65 (residue C-443) to valine prevents the binding to ␤APP. Furthermore, conversion of cysteine 443 in FE65 to phenylalanine also abolishes the binding of FE65 PI (C) to ␤APP (Fig. 6B ). This strengthens our evidence that the target for the FE65 PI domains differs from that for X11 and possibly other PI domains that have a conserved phenylalanine at this position. A residue that is conserved in all PI domains is the serine residue at amino acid 151 of p52 Shc (58) . In the nuclear magnetic resonance structure, this residue is involved in complexing the Shc PI/PTB domain with phosphotyrosine (59). We and others have shown that mutation of this serine to alanine in Shc can impair binding to EGF receptor (58, 59), but in X11 this mutation is without effect (Fig.  6A ). This may serve as further confirmation that phosphotyrosine is not involved in the binding of X11 to ␤APP.
In the experiment whose results are shown in Fig. 7 , we examined whether X11 and FE65 PI domains can bind several proteins in cells or if their binding specificity is more restricted. We labeled the PC12 cell line with [ 35 S]methionine and performed precipitation with GST-FE65 PI (C) or X11 PI domains immobilized on glutathione-agarose beads. In agree- VOL. 16, 1996 BINDING OF X11 AND FE65 TO ␤APP 6235 ment with previous results (20), we found that FE65 PI (C) bound to two sets of proteins. One group of FE65-binding proteins had a molecular mass similar to that of ␤APP, while the other major protein detected migrated at 51 kDa. This 51-kDa protein could be a breakdown product of ␤APP, but we have not detected this protein in anti-␤APP immunoblots. The mutation of cysteine 443 to valine of FE65 PI (C) described above abolished the binding to both sets of proteins. For X11, we found exclusive binding of X11 to proteins with molecular masses similar to that of ␤APP, indicating that ␤APP is likely to be the main binding partner for X11. Mutation of phenylalanine 479 to valine eliminated the binding of the X11 PI domain. Overall, our results indicate that ␤APP is likely the major binding target for X11 and FE65 in PC12 cells. We next asked whether mutations of ␤APP, FE65, and X11 that blocked in vitro interactions would also affect interaction of full-length proteins in living cells. In the experiment whose results are shown in Fig. 8 , we used mutations of FE65 and X11 at the residue analogous to F-198 of p52 Shc. We transfected 293 cells with wild-type FE65-myc and FE65-myc with cysteine 443 mutated to valine (Fig. 8A) . In agreement with our in vitro data, mutation of this cysteine severely impaired the binding of FE65 to ␤APP. These data reinforced the important role of the carboxy-terminal FE65 PI domain in mediating binding of FE65 to ␤APP. Similarly, we found that mutation of the phenylalanine at residue 479 of X11 blocked the interaction of full-length X11 with ␤APP in 293 cells (Fig. 8B) . In a similar set of experiments, we looked at the effect of mutation of full-length ␤APP on the binding of X11 and FE65. Two point mutations that had been shown previously (Fig. 5) to affect X11 and FE65 PI domain binding were studied. One mutation converted tyrosine 682 of ␤APP to glycine (Y682G), while the other changed asparagine 684 of ␤APP to alanine (N684A) (Fig. 9) . We found that mutation of Y682 to G682 impaired the binding of both X11 and FE65, while mutation of N684 to A684 affected X11 binding but not FE65 binding. These results were identical to data we had obtained using isolated PI domains of FE65 and X11 (Fig. 5 ).
DISCUSSION
In this study, we have further defined the binding of FE65 to ␤APP and identified a new binding partner for ␤APP, the X11 protein. These interactions with ␤APP involve the YENPTY motif of ␤APP, a motif that may be crucial for the processing of ␤APP (15, 29) . We have demonstrated the interactions between these proteins by coimmunoprecipitation in living cells and by using purified bacterial proteins. Both X11 and FE65 interact with ␤APP via their PI domains. FE65 has two PI domains, and we have narrowed the major site of interaction to the carboxy-terminal PI domain. From using [
35 S]methionine-labeled lysates, it appears that ␤APP is the major binding partner for the PI domain of X11 and the carboxyterminal PI domain of FE65. We have identified a mutation that can block binding of both the FE65 and the X11 PI domains to ␤APP. This mutation affects a residue previously identified as crucial in the interactions of Shc PI/PTB domain with phosphopeptide (58) . However, there is no evidence indicating that phosphorylation is crucial for the interaction of FE65 or X11 with ␤APP. While both FE65 and X11 bind to the cytoplasmic domain of ␤APP, the exact sites of interaction on ␤APP appear to differ. Mutation of the amino-terminal tyrosine in the YENPTY motif of ␤APP abolishes interaction of both X11 and FE65 with ␤APP, while mutation of the asparagine in this motif inhibits only X11 binding. Furthermore, a peptide encompassing the YENPTY motif can inhibit X11 binding but not FE65 binding to ␤APP.
This study further defines the role of PI domains in proteinprotein interactions. When the Shc PI domain was identified, the existence of PI domains in several other proteins was demonstrated (3, 4) . The results reported here confirm that some of these other PI domains are also involved in protein-protein interactions. X11 has the PI domain closest in sequence to the Shc PI/PTB domain, with 23% identity over 162 amino acids. Thus, it might not be surprising that its binding specificity is related to that of the Shc PI domain. Both domains appear to contact ⌿XNPXY motifs, although there are similarities and differences in the binding specificities. The most important difference is that phosphorylation of the carboxy-terminal tyrosine is required for high-affinity binding of the Shc PI domain to the ⌿XNPXY motif. In our study, we obtained compelling evidence that tyrosine phosphorylation of the ␤APP YENPTY motif is not required for the interaction with X11 or FE65 PI domains. First, mutation of the carboxy-terminal tyrosine to alanine does not interfere with binding. Second, a nonphosphorylated peptide from ␤APP inhibited binding of the X11 peptide with apparent submicromolar affinity. The same affinity was measured with a peptide in which the carboxy-terminal tyrosine of the YENPTY motif was phosphorylated. Third, ␤APP produced in bacteria or ␤APP that was dephosphosphorylated with PAP bound to X11. Fourth, mutation of the conserved serine found in both X11 and Shc markedly affected Shc PI/PTB binding but had no effect on X11 PI domain binding. In the Shc PI/PTB domain, this serine is involved in complexing phosphotyrosine. In contrast to the effects of the serine mutation, mutagenesis of the conserved phenylalanine at residue 198 of p52 Shc and residue 479 of X11 resulted in a loss of PI domain binding activity for both Shc and X11. Since in Shc this phenylalanine interacts with the Ϫ5 hydrophobic amino acid and the Ϫ3 asparagine on the contact phosphopeptide, it is likely that the same occurs in X11 (59) . In agreement, mutation of the Ϫ5 hydrophobic amino acid or the Ϫ3 asparagine on ␤APP abolishes binding to X11. It has recently been suggested that the Shc PI/PTB domain can bind to an NPLH motif on the protein tyrosine phosphatase-PEST (8) . This seems to indicate that tyrosine phosphorylation may not always be required for Shc PI/PTB binding. However, it must be noted that the affinity of the NPLH peptide for the Shc PI/PTB domain was approximately 10-fold lower than those of phosphotyrosine-containing peptides. It was suggested that the histidine residue in the NPLH motif may require posttranslational modification for high-affinity binding, suggesting a possible role for phosphohistidine in the interaction.
The binding of FE65 to ␤APP appears to be mediated by the carboxy-terminal PI domain. Expression of both PI domains of FE65 as fusion proteins led to binding only to FE65 PI (C) even though both PI domains were easily expressed. Furthermore, mutation of FE65 PI (C) in full-length FE65 severely impaired the interaction between FE65 and ␤APP. As is the case for X11, we can see no evidence that phosphorylation plays a role in ␤APP binding to FE65. However, the binding specificity of FE65 PI (C) is different from that of the X11 PI domain. As shown in Fig. 5C , a peptide centered on the YENPTY motif can block X11 but not FE65 binding. Furthermore, mutation of the asparagine in the YENPTY motif abolished binding of X11 but not FE65. However, the binding sites for FE65 and X11 overlap somewhat in that an 18-amino-acid deletion of the carboxy terminus or mutation of amino-terminal tyrosine in the YENPTY motif prevents the binding of both FE65 and X11. The fact that the binding specificities of the FE65 and X11 PI domains are different is not surprising. VOL. 16, 1996 BINDING OF X11 AND FE65 TO ␤APP 6237 domain (13%). We hypothesized that the FE65 PI domains might have binding specificities different from those of other PI domains because the FE65 PI domains have a cysteine rather than a phenylalanine at a position analogous to residue 198 of p52 Shc (58) . Further work will be necessary to delineate the exact binding specificity of FE65 PI (C) and to determine if X11 and FE65 might compete for the same binding site. Although originally termed phosphotyrosine interaction or phosphotyrosine binding domains, these names do not seem appropriate for the PI domains of X11 and FE65, which do not require phosphotyrosine in their binding target. On the basis of the structural data for the Shc PI/PTB domain, it can be surmised that these domains are structurally related to pleckstrin homology (PH) domains (59) . However, although structurally related, there appear to be few data that tie the function of PH domains with that of PI/PTB domains. Thus, for now, we choose to refer to domains that fit within our initial alignment (4, 58) as PI domains, for protein interaction domains. We argue that these domains are one subclass of PH domains that are involved in protein-protein interactions and may have a predilection for NPXY motifs. In fact, Gustafson and coworkers originally termed the PI/PTB domains of Shc and IRS-1 SAIN domains, for Shc and IRS-1 binding NPXY motifs (23) . The PI/PTB domains of Shc and IRS-1 might be unique in that they appear to have evolved to require phosphotyrosine for high-affinity binding to an NPXY motif. The binding partners for more members of the PI and PH domain family need to be identified before final nomenclature can be resolved. It seems likely that other PI domains will bind to nonphosphorylated targets. An example may be the very recently described binding Another implication for this work, outside the role of PI domains, is its impact on Alzheimer's disease biology. It has been shown that deletion of the YENPTY motif on ␤APP affects the production of ␤APP breakdown products. Deletion of the YENPTY motif leads to increased production of the carboxy-terminal truncated and secreted form of ␤APP while decreasing the production of the amyloidgenic A␤ protein (15, 29) . It is theorized that some of the A␤ production occurs because of internalization of ␤APP via clathrin-coated pits and that the YENPTY motif might be crucial in this process (11, 31, 38) . The molecular basis of action for the YENPTY motif is unclear, but our results suggest that proteins binding to this motif might be responsible. Both FE65 and X11 could bind ␤APP into other protein complexes, as both have additional protein interaction domains. FE65 has a WW domain on its amino terminus, a domain known to bind to proteins with proline-rich motifs (10, (49) (50) (51) . Similarly, X11 has two PDZ motifs. PDZ motifs have been implicated in the binding of sequences similar to (S/T)XV (where S is serine, T is threonine, X is any amino acid, and V is valine) found on Fas and N-methyl-D-aspartate receptors. These domains are also implicated in PDZ dimerization such as occurs between PDZ domains on nitric oxide synthase and PSD95 (5, 6, 17, 30, 44) . Thus, it will be important to determine what other proteins are complexed with ␤APP when it is bound to FE65 or X11. These complexes could play an important role in the processing of ␤APP or might play a role in the normal physiologic function of ␤APP. The effects of X11 and FE65 might lead to cellspecific patterns of ␤APP processing or signaling or both. X11 and FE65 have been localized to cells of the nervous system (18, 46) . However, there may be proteins highly related to FE65 and X11 expressed in many cells. For example, there may be many forms of X11 given the fact that the mouse and human X11 proteins are quite divergent in their amino termini. Similarly, at least two forms of FE65 have been identified in the database, FE65 and FE65-like protein (4) .
In summary, this work has further defined the binding motif for PI domains. The PI domains appear structurally related to PH domains. While it has been difficult to define ligand for PH domains, the PI domains appear to bind peptide sequences. In the case of X11 and Shc, these sequences appear to center on NPXY motifs. It is tempting to speculate that PI domains may play a role in the physiologic function of NPXY motifs to mediate internalization. However, although X11 binds to the YENPTY motif on ␤APP, it does not bind similar motifs on the low-density lipoprotein receptor (FDNPVY) or on the lowdensity-lipoprotein-related receptor (IGNPTY and FTNPVY) (3a) . Additionally, the X11 PI domain does not bind to the numerous NPXY motifs found on EGF receptor (VQNPVY, VGNPVY, or LDNPDY; Fig. 1C ). This indicates a high degree of selectivity in PI domain binding and suggests that there may be undiscovered PI domains or related domains that bind to NPXY motifs on these proteins. The implications of our findings may have an impact on the pathways for processing of ␤APP. Both FE65 and X11 bind near or at the YENPTY motif and as such may direct the internalization and processing of ␤APP. Even if these proteins are not responsible for the ␤APP processing, their presence may modify the binding of other factors to this motif, leading to regulation of ␤APP processing. We have defined mutations in ␤APP, FE65, and X11 that can FIG. 9 . Association between ␤APP and FE65 or X11 is disrupted by a single mutation in the ␤APP cytoplasmic domain. Cotransfection experiments were performed in 293 cells with RK5-␤APP 695 (W.T. APP), RK5-Y682G ␤APP (Y682G APP), or RK5-N684A ␤APP (N684A APP) constructs and RK5-FE65-myc or RK5-myc-X11. Lysates were run on a 10% polyacrylamide-SDS gel, and transferred proteins were revealed by anti-␤APP antibody (upper panels). In parallel, the same lysates were incubated with anti-myc antibody and immunoprecipitated proteins were sequentially revealed by 369 anti-␤APP (middle panels) and anti-myc antibodies (lower panels) after Western blotting. The ␤APP position is indicated (arrow). In this experiment, the level of expression of the N684A ␤APP protein was lower than that of the wild-type and Y682G ␤APP. Accordingly, the membrane was exposed for 30 instead of 5 s to reveal ␤APP protein in cells transfected with the N684A mutant.
VOL. 16, 1996 BINDING OF X11 AND FE65 TO ␤APP 6239 block these interactions, and these mutations will serve as valuable tools with which to define the physiologic relationship of ␤APP to X11 and FE65.
